Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Targets

PITTSBURGH, Could 16, 2022 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS), a world pharmaceutical firm, revealed in the present day its 2021 Sustainability Reportoutlining the corporate’s 2021 achievements and progress throughout key areas together with Entry and World Well being, Workers, Environmental Stewardship and Group Engagement and together with particulars on Viatris’ continued efforts to help workers and their households whereas sustaining a secure provide of medicines through the ongoing COVID-19 pandemic.

Download the Viatris 2021 Sustainability Report Fact Sheet

Obtain the Viatris 2021 Sustainability Report Reality Sheet

As a part of the report, the corporate dedicated to preliminary company-wide and multi-year objectives in three key areas – entry, the atmosphere and variety, fairness and inclusion (DE&I). These embody offering antiretroviral (ARV) remedy equal to a complete of 30 million sufferers, together with greater than two million youngsters residing with HIV/AIDS, between 2022 and the top of 2025; impacting 100 million sufferers through healthcare skilled schooling and outreach concerning prevention, prognosis and therapy choices for heart problems, diabetes, most cancers and different essential power circumstances to enhance outcomes by way of the NCD Academy by the top of 2025. Viatris has dedicated to decreasing absolute Scope 1 and a couple of greenhouse gasoline (GHG) emissions 42% by 2030 and decreasing Scope 3 GHG emissions protecting buy items and providers, capital items, gas and power associated alternate options and upstream transportation and distribution 25% by 2030. The corporate has additionally set objectives to boost DE&I in help of attracting, growing and retaining various expertise and constructing a extra inclusive atmosphere.

“At Viatris, we imagine firms is usually a pressure for good. Our colleagues world wide attempt to make a constructive distinction and through our first full yr as Viatris, they really exemplified the ability that lies in collaboration, focus and resilience,” stated Michael Goettler, CEO for Viatris. “We’re pleased with the robust basis we’ve constructed, the progress we’ve made and our dedication to performing responsibly as we help offering sustainable entry to medication for sufferers world wide, no matter geography or circumstance, whereas constructing an easier, stronger and extra centered firm.”

Listed below are a few of Viatris’ key initiatives, progress and accomplishments in 2021, in collaboration with our companions:

  • Roughly 40% of adults and greater than 60% of kids being handled for HIV used a Viatris product

  • Greater than 80 billion doses of drugs bought throughout greater than 165 nations and territories, reaching roughly 90% of low- and lower-middle-income nations with roughly 7.7 billion doses

  • Established a proper program for constructing DE&I, starting with understanding the present make-up of our workforce to tell how we’ll embed DE&I all through the group, help illustration and improve the worker expertise general

  • Signed on to the UN World Compact CEO Water Mandate different UN Girls’s Empowerment Rules

  • Roughly 500 million doses of medicines donated throughout quite a lot of therapeutic areas by working by way of a trusted community of companions

“At Viatris, our dedication to entry to medication and supporting resilient healthcare programs by advancing sustainable and accountable operations actually is a collective mission, realized by way of the dedication of colleagues throughout the group,” stated Laura RamsburgHead of Company Affairs of Viatris.

Viatris is devoted to clear annual reporting on environmental, social and governance issues, constantly working to additional improve its disclosures.

To study extra about how the corporate companions with stakeholders all through the globe to deal with a few of the world’s most urgent well being, environmental and social points, click on right here.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a brand new sort of healthcare firm, empowering individuals worldwide to dwell more healthy at each stage of life. We offer entry to medicines, advance sustainable operations, develop revolutionary options and leverage our collective experience to attach extra individuals to extra services and products by way of our one-of-a-kind World Healthcare Gateway®. Fashioned in November 2020, Viatris brings collectively scientific, manufacturing and distribution experience with confirmed regulatory, medical, and business capabilities to ship high-quality medicines to sufferers in additional than 165 nations and territories. Viatris’ portfolio includes greater than 1,400 accepted molecules throughout a variety of therapeutic areas, spanning each non-communicable and infectious ailments, together with globally acknowledged manufacturers, complicated generic and branded medicines, a portfolio of biosimilars and quite a lot of over-the-counter shopper merchandise. With roughly 37,000 colleagues globally, Viatris is headquartered within the US, with world facilities in Pittsburgh, Shanghai different Hyderabad, India. Study extra at viatris.com different investor.viatris.comand join with us on Twitter at @ViatrisInc, LinkedIn different YouTube.

Ahead-looking statements
This press launch contains statements that represent “forward-looking statements.” These statements are made pursuant to the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. Such ahead trying statements might embody statements concerning the firm committing to preliminary company-wide and multi-year objectives in three key areas – entry, the atmosphere and DE&I; that these embody offering antiretroviral (ARV) remedy equal to a complete of 30 million sufferers, together with greater than two million youngsters residing with HIV/ AIDS, between 2022 and the top of 2025; affect 100 million sufferers through healthcare skilled schooling and outreach concerning prevention, prognosis and therapy choices for heart problems, diabetes, most cancers and different essential power circumstances to enhance outcomes by way of the NCD Academy by the top of 2025; that Viatris has dedicated to decreasing absolute Scope 1 and a couple of greenhouse gasoline (GHG) emissions 42% by 2030 and decreasing Scope 3 GHG emissions protecting buy items and providers, capital items, gas and power associated alternate options and upstream transportation and distribution 25% by 2031 ; and that the corporate has additionally set objectives to boost DE&I in help of attracting, growing and retaining various expertise and constructing a extra inclusive atmosphere. As a result of forward-looking statements inherently contain dangers and uncertainties, precise future outcomes might differ materially from these expressed or implied by such statements. Elements that would trigger or contribute to such variations embody, however usually are not restricted to: the potential affect of public well being outbreaks, epidemics and pandemics, together with the continuing challenges and uncertainties posed by the COVID-19 pandemic; the pending transaction between Viatris and Biocon Biologics Restricted, pursuant to which Viatris will contribute its biosimilar merchandise and applications to Biocon Biologics in trade for money consideration and a convertible most popular fairness curiosity in Biocon Biologics, might not obtain its meant advantages; the combination of Mylan NV and Pfizer Inc.’s Upjohn enterprise (the “Upjohn Enterprise”), which mixed to kind Viatris (the “Mixture”) and the implementation of our world restructuring initiatives being harder, time consuming or expensive than anticipated , or being unsuccessful; the flexibility to realize anticipated advantages, synergies, and working efficiencies in reference to the mixture or its restructuring initiatives throughout the anticipated timeframe or in any respect; actions and choices of healthcare and pharmaceutical regulators; adjustments in healthcare and pharmaceutical legal guidelines and rules within the US and overseas; any regulatory, authorized or different impediments to Viatris’ capability to convey new merchandise to market, together with however not restricted to “at-risk” launches; Viatris’ or its companions’ capability to develop, manufacture, and commercialize merchandise; the scope, timing and end result of any ongoing authorized proceedings, and the affect of any such proceedings; any important breach of information safety or information privateness or disruptions to our info expertise programs; dangers related to worldwide operations; the flexibility to guard mental property and protect mental property rights; adjustments in third-party relationships; the impact of any adjustments in Viatris’ or its companions’ buyer and provider relationships and buyer buying patterns; the impacts of competitors; adjustments within the financial and monetary circumstances of Viatris or its companions; uncertainties and issues past the management of administration; and the opposite dangers described in Viatris’ filings with the Securities and Change Fee (SEC). Viatris routinely makes use of its web site as a method of revealing materials info to the general public in a broad, non-exclusionary method for functions of the SEC’s Regulation Truthful Disclosure (Reg FD). Viatris undertakes no obligation to replace these statements for revisions or adjustments after the date of this launch apart from as required by legislation.

Viatris logo (PRNews photo/Viatris Inc.)

Viatris emblem (PRNews picture/Viatris Inc.)

surgery

surgical procedure

View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/viatris-publishes-sustainability-report-highlighting-2021-progress-achievements-and-goals-301547592.html

SOURCE Viatris Inc.

Leave a Comment